article thumbnail

Market analysts predict $44 billion in obesity drug sales in 2030

Drug Discovery World

Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs $2.5 The post Market analysts predict $44 billion in obesity drug sales in 2030 appeared first on Drug Discovery World (DDW). billion in 2022, with just under 70% stemming from the US.

Marketing 130
article thumbnail

Window to avoid 1.5°C of warming will close before 2030 if emissions are not reduced

Science Daily: Pharmacology News

°C of warming before 2030. Without rapid carbon dioxide emission reductions, the world has a 50% chance of locking in 1.5°C

88
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AstraZeneca sets sights on $80B in revenue by 2030

BioPharma Drive: Drug Pricing

pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.

Treatment 119
article thumbnail

AZ to invest $400 million in reforestation and biodiversity

Drug Discovery World

AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030. The company is on track to reduce greenhouse gas emissions (GHGs) from its operations and fleet by 98% by 2026 and halve its value chain footprint by 2030.

Science 246
article thumbnail

New eBook: Using imaging in drug discovery

Drug Discovery World

billion by 2030, growing at a CAGR of 15.3% from 2023 to 2030. According to a January 2024 report by market analysts Coherent Market Insights, the global bio-imaging market was estimated to be worth $5.74 billion in 2023 and is poised to reach $15.58

Drugs 130
article thumbnail

Positive results announced for COPD therapy

Drug Discovery World

By 2030, it’s estimated that the global cost of COPD will rise to $4.8 trillion by 2030 1 , indicating a serious unmet need for new and improved therapeutics. Damage of this barrier is implicated in several chronic inflammatory diseases, including COPD.

Therapies 130
article thumbnail

Charles River achieves 92% renewable energy use

Drug Discovery World

The company reported a reduction of Scope 1 and 2 global greenhouse gas (GHG) emissions by 37% over the last five years, targeting a 50% reduction by 2030. It achieved 92% renewable electricity usage globally, working toward the deployment of 100% renewable electricity across operations by 2030.

FDA 130